EVALUATION OF THE EFFICACY OF AN IMMUNOREGULATORY PEPTIDE IN THE COMBINATION THERAPY OF CHILDREN WITH PNEUMONIA
https://doi.org/10.21508/1027-4065-2016-61-6-109-112
Abstract
Objective: to evaluate the efficacy of an immunoregulatory peptide in the combination therapy of pneumonia in children. The investigation included 71 children aged 1 to 15 years with pneumonia. According to the days of the week, the patients were randomized into 2 groups: 1) 32 children received standard combination therapy; 2) 39 children took an immunoregulatory peptide (the active ingredient was arginyl-alpha-aspartyl-lysyl-valyl-tyrosyl-arginine) as a nasal spray at a dose of 50 µg in addition to the standard therapy. The efficacy of the agent was evaluated by the duration and severity of the major clinical symptoms of the disease and the levels of cytokines and bactericidal/permeability-increasing protein. The immunoregulatory peptide was ascertained to be effective in treating children with pneumonia since it decreased the duration and severity of the major clinical symptoms and normalized immunological parameters.
About the Authors
S. V. Shabalina
ФБУН «Центральный НИИ эпидемиологии» Роспотребнадзора, Москва, Россия
Russian Federation
Central Research Institute of Epidemiology, Federal Service for Surveillance of Customer Rights Protection and Human Welfare, Moscow, Russia
Russian Federation
Central Research Institute of Epidemiology, Federal Service for Surveillance of Customer Rights Protection and Human Welfare, Moscow, Russia
A. V. Tutelian
Central Research Institute of Epidemiology, Federal Service for Surveillance of Customer Rights Protection and Human
Welfare, Moscow, Russia
Russian Federation
Russian Federation
References
1. Таточенко В.К. Болезни органов дыхания у детей. Москва: ПедиатрЪ, 2012; 497. (Tatochenko V.K. Diseases of the respiratory system in children. Moscow: Pediatr, 2012; 497. (in Russ.))
2. Баранов А.А., Багненко С.Ф., Намазова-Баранова Л.С. Федеральные клинические рекомендации по оказанию скорой медицинской помощи при внебольничной пневмонии у детей. 2015; 12. (Baranov A.A., Bagnenko S.F., Namazova-Baranova L.S. Federal clinical recommendations on the provision of emergency medical services in community-acquired pneumonia in children. 2015; 12. (in Russ.))
3. Чучалин А.Г., Геппе Н.А., Розинова Н.Н. и др. Научно-практическая программа Российского респираторного общества: внебольничная пневмония у детей: распространенность, диагностика, лечение и профилактика. Москва 2012; 63. (Chuchalin A.G, Geppe N.A., Rozinova N.N. et al. Scientific-practical program of the Russian respiratory society: community-acquired pneumonia in children: prevalence, diagnosis, treatment and prevention. Moscow 2012; 63. (in Russ.))
4. Мизерницкий Л.Ю., Царегородцев А.Д. Пульмонология детского возраста: проблемы и решения. Сборник. Выпуск 9, Москва 2009; 200. (Mizernickij L.Yu., Tsaregorodcev A.D. Pulmonology of childhood: problems and solutions. Moscow 2009; 200. (in Russ.))
5. Пневмония. Информационный бюллетень № 331 Ноябрь 2015 г.
6. http://www.who.int/mediacentre/factsheets/fs331/ru/ (Pneumonia. Newsletter № 331 November 2015. http:// www.who.int/mediacentre/factsheets/fs331/ru/)
7. Чучалин А.Г., Авдеев С.Н., Архипов В.В. и др. Рациональная фармакотерапия заболеваний органов дыхания. Руководство для практикующих врачей. Москва: Литера 2004; 873. (Chuchalin A.G., Avdeev S.N., ArhipovV.V. et al. Rational pharmacotherapy of respiratory diseases. A guide for practitioners. Moscow: Litera 2004; 873. (in Russ.))
8. Синопальников А.И., Козлов Р.С. Внебольничные инфекции дыхательных путей. Москва 2007; 352. (Sinopal’nikov A.I., Kozlov R.S. Community-acquired respiratory tract infections. Moscow 2007; 352. (in Russ.))
9. Заплатников А.Л., Гирина А.А., Бурцева Е.И. Иммунопрофилактика гриппа и других острых респираторных вирусных инфекций в достижении контроля над течением бронхиальной астмы. Педиатрия 2013; 51–56. (Zaplatnikov A.L., Girina A.A., Burceva E.I. Immunoprophylaxis of influenza and other acute respiratory viral infections in the achievement of control over bronchial asthma. Pediatrija 2013; 51–56. (in Russ.))
10. Лебедев В.В., Шелепова Т.М., Степанов О.Г. и др. Имунофан-регулярный пептид в терапии инфекционных и неинфекционных болезней Москва 2008; 120. (Lebedev V.V., Schelepova T.M., Stepanov O.G. et al. Imunofan in therapy of infectious and non-infectious diseases. Moscow 2008; 120. (in Russ.))
11. Караулов А.В. Клинико-иммунологическая эффективность применения имунофана при оппортунистических инфекциях. Москва: ООО НПП Бионокс 2010; 19–22. (Karaulov A.V. Clinical and immunological efficacy of imunofana of opportunistic infections. Moscow: OOO NPP Bionoks 2010; 19–22. (in Russ.))
12. Степанов О.Г., Данилин А.В., Лебедев В.В. Гормоны иммунитета и регуляторные пептиды в патогенезе и терапии иммунных расстройств. Москва 2002; 1: 53–59. (Stepanov O.G., Danilin A.V., Lebedev V.V. Immunity hormones and regulatory peptides in the pathogenesis and therapy of immune disorders. Moscow 2002; 1: 53–59. (in Russ.))
13. Кубанова А.А., Спектор А.Г. Клиническая эффективность применения имунофана у больных псориазом. Москва: ООО НПП Бионокс 2010; 42. (Kubanova A.A., Spektor A.G. Clinical efficacy of imunofana in patients with psoriasis. Moscow: OOO NPP Bionoks 2010; 42. (in Russ.))
14. Железнякова Г.Ф. Роль цитокинов в патогенезе и диагностике инфекционных заболеваний. Инфекционные болезни 2008; 6: 3: 70–76. (Geleznjakova G.F. The role of cytokines in pathogenesis and diagnosis of infectious diseases. Infekcionnye bolezni 2008; 6: 3: 70–76. (in Russ.))
15. Железнякова Г.Ф. Цитокины как предикторы течения и исхода инфекций. Цитокины и воспаление 2009; 8: 1: 10–17. (Geleznjakova G.F. Cytokines as predictors of course and outcome of infections. Citokiny i vospalenie 2009; 8: 1: 10–17. (in Russ.))
16. Michelow J, Katz K., Mc Cracken G. et al. Systemic cytokine profile in children with community-acguierd pneumonia. Pediatr Pulmonol 2007; 42: 7: 640–645.
17. Canny G., Levy O., Furuta G. et al. Lipid mediator-induced expression of bactericidal permeability-increasing protein (BPI) in human mucosal epithelia. Proc Nat Acad Sci USA 2002; 99: 6: 3902–3907.
18. Di Y.P., Harper R., Zhao Y. et al. Molecular cloning and char-acterization of spurt, a human novel gene that is retinoic acid-inducible and encodes a secretory protein specific in upper respiratory tracts. Biol Chem 2003; 278: 1165–1173.
19. Elson G., Dunn-Siegrist I., Daubeuf B., Pugin J. Contribution of Toll-like receptors to the innate immune respons to Gram-negative and Gram-positive bacteria. Blood 2007; 109: 1574–1583.
20. Заплатников А.Л., Гирина А.А., Коровина Н.А. и др. Часто болеющие дети: причины недостаточной эффективности оздоровления и резервы иммунопрофилактики. Российский медицинский журнал 2015; 3: 178. (Zaplatnikov A.L. , Girina A.A., Korovina N.A. et al. Sickly children: the reasons of insufficient efficiency improvement and reserves of immunization. Rossijskij medicinskij zhurnal 2015; 3: 178. (in Russ.))
Review
For citations:
Shabalina S.V., Tutelian A.V. EVALUATION OF THE EFFICACY OF AN IMMUNOREGULATORY PEPTIDE IN THE COMBINATION THERAPY OF CHILDREN WITH PNEUMONIA. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2016;61(6):109-112. (In Russ.) https://doi.org/10.21508/1027-4065-2016-61-6-109-112
Views:
984
Email this article 